Conference Correspondent

Based on the premise that BCL-2 may play a key role in HER2-positive breast cancer, a phase 1b/2, randomized, placebo-controlled trial will evaluate venetoclax plus trastuzumab emtansine. Read More ›

De-escalation of adjuvant cytotoxic chemotherapy among patients who experienced pathologic complete response in early-stage HER2-positive breast cancer appears to be an acceptable approach for both patients and physicians. Read More ›

Treatment-related amenorrhea with a standard combination chemotherapy regimen occurred at a rate that was nearly double that observed with trastuzumab emtansine plus pertuzumab, implying that gonadal function may be preserved through an antibody–drug conjugate regimen. Read More ›

Among patients with HER2-positive metastatic breast cancer, the healthcare resource utilization of brain metastases is significantly higher when compared with patients without brain metastases, underscoring the critical need for effective systemic therapies that improve outcomes and decrease the burden of disease. Read More ›

Identified subpopulations of patients showed the largest absolute advances in 6-year invasive disease-free survival for pertuzumab compared with placebo. Read More ›

This real-world study of community-based oncology clinics demonstrates that patients receive variable treatment patterns in later line settings, and there is no clear management strategy being utilized. With recently approved targeted therapies for HER2-positive metastatic breast cancer, improvements in patient outcomes are slowly being seen. Read More ›

The potential role of the combination of pertuzumab, hormone therapy, plus an aromatase inhibitor as first-line treatment for HER2-positive metastatic or locally advanced breast cancer is further supported by the final analysis of the PERTAIN trial. Read More ›

Elderly patients with HER2-positive advanced breast cancer demonstrated shorter chemotherapy durations, poorer overall survival, and increased rates of adverse events, emphasizing the need for prospective studies to improve outcomes. Read More ›

Among patients with acute myeloid leukemia (AML), venetoclax added to a low-intensity backbone of cladribine plus low-dose Ara-C alternating with 5-azacitidine was an effective, well-tolerated regimen. Read More ›

No new safety signals associated with gilteritinib were found in a study comparing gilteritinib + azacitidine with azacitidine alone in patients with newly diagnosed, FLT3-mutated AML. A composite response rate of 67% was found among patients in the safety cohort receiving gilteritinib + azacitidine. Read More ›